Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALX-0061 Bioavailability in Healthy Volunteers
NCT02101073Phase 1Completed
- Sponsor
- Sanofi
- Start
- Mar 2014
- Primary completion
- Jul 2014
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vobarilizumab in rheumatoid arthritis (RA) (5 arms), sponsored by Sanofi. Primary endpoint: Pharmacokinetics: serum concentration of ALX-0061. Started Mar 2014; status: completed.
02
Drugs
vobarilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02101073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02101073.